NCT02156739 - Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 13, 2014

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions

Hepatocellular CarcinomaLiver and Intrahepatic Bile Duct DisorderMetastatic Malignant Neoplasm in the LiverPrimary Malignant Liver Neoplasm

Interventions

PROCEDURE

Contrast-enhanced Magnetic Resonance Imaging

Undergo contrast-enhanced MRI

DRUG

Gadobutrol

Given IV

DRUG

Gadoxetate Disodium

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER